Riyad Elbard

Health Canada Approves REBLOZYL® For Adult Patients with β-Thalassaemia
Actualités

Health Canada Approves REBLOZYL® For Adult Patients with β-Thalassaemia

Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL® (luspatercept) for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia…
Bouton retour en haut de la page